C-o- Group In R Patents (Class 514/622)
-
Publication number: 20130195936Abstract: The present invention refers to an oil-in-water emulsion for ophthalmic application comprising at least one prostaglandin as active agent and a surfactant component comprising a combination of at least two non-ionic surfactants. The emulsion is suitable for medical applications, particularly for the treatment of glaucoma, and has an increased chemical stability of the prostaglandin active agent so to allow long-term storage also at room temperature.Type: ApplicationFiled: March 14, 2013Publication date: August 1, 2013Applicant: AZAD PHARMA AGInventor: AZAD Pharma AG
-
Publication number: 20130190272Abstract: The present invention provides a composition having an excellent controlling activity on a pest. The composition comprising a compound represented by Formula (1) and one or more pyrethroid compound(s) selected from Group (A) shows an excellent controlling activity on a pest.Type: ApplicationFiled: October 13, 2011Publication date: July 25, 2013Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: So Kiguchi, Soichi Tanaka
-
Publication number: 20130178517Abstract: Disclosed are methods of treatment for adipogenic virus-related conditions. The methods may comprise administering a composition comprising an effective dose of an antiviral agent to a subject having an adipogenic adenovirus-related condition. Administration of the antiviral agent may prevent or reduce viral proliferation in the subject. The method may also include administering a composition comprising an effective dose of a therapeutic agent known to treat the adipogenic adenovirus-related condition in conjunction with the composition comprising an effective dose of an antiviral agent. Administration of the antiviral agent and the therapeutic agent may reduce or eliminate one or more symptoms of the adipogenic adenovirus-related condition more efficiently than administration of either the antiviral agent and the therapeutic agent alone.Type: ApplicationFiled: July 8, 2011Publication date: July 11, 2013Inventors: Richard L. Atkinson, Zendra Pei-lun Lee, Jia He
-
Patent number: 8481593Abstract: The invention relates to the use of para-coumaric acid or para-hydroxycinnamic acid derivatives in cosmetic or dermatological compositions, specifically to the use of at least one compound derived from para-coumaric acid having a general formula (I) below: in which, especially, Z represents an oxygen or an —NH— group; X and Y are identical and each represent a CH or CH2 group, as an active principle with depigmenting, free-radical-scavenging and/or antiinflammatory activity. The invention also relates to the use of the above compounds for cosmetic care or for the preparation of a pharmaceutical composition, especially for depigmenting an area of skin, having antiradical and/or antiinflammatory activity.Type: GrantFiled: June 3, 2011Date of Patent: July 9, 2013Assignees: BASF Beauty Care Solutions S.A.S., Universite Joseph Fourier-Grenoble 1Inventors: Sabrina Okombi, Delphine Rival, Ahcene Boumendjel, Anne-Marie Mariotte, Eric Perrier
-
Publication number: 20130157963Abstract: Compositions and methods related to ophthalmic use of polyvinyl capralactam-polyvinyl acetate-polyethylene glycol graft copolymers and therapeutic uses are described herein.Type: ApplicationFiled: December 14, 2012Publication date: June 20, 2013Applicant: ALLERGAN, INC.Inventor: ALLERGAN, INC.
-
Publication number: 20130158112Abstract: A pharmaceutical composition for inhibiting amyloid beta peptide in a subject includes a compound having the formula (I): where M is selected from a substituted or unsubstituted alkyl, halo, alkoxy, aryl, cyclic, or heterocyclic group; p is an integer from 0-3; X1 is a 3-9 atoms in length linker connecting A and B; B is selected from a substituted or unsubstituted aryl, alkoxy or amine group; and a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier.Type: ApplicationFiled: June 20, 2012Publication date: June 20, 2013Inventors: Jonathan D. Smith, Enakshi Chakrabarti, Subrata Ghosh, Marti Sayre, Gregory Tochtrop
-
Patent number: 8466126Abstract: Compositions, kits and methods are provided for conditioning, revitalizing, volumizing or increasing the natural pigmentation of the hair, including hair on the scalp, eyelashes, eyebrows, mustache and beard, promoting healthy growth, and treating and preventing loss, thinning or miniaturization of hair due to aging, various genetic, pathological, radiation, chemotherapy, chemical treatment, environmental or other reasons.Type: GrantFiled: October 27, 2010Date of Patent: June 18, 2013Assignee: Jan Marini Skin Research, Inc.Inventor: Jan Marini
-
Publication number: 20130150416Abstract: The present invention discloses methods of modulating the activity of Group I mGluRs using a defined class of benzamide compounds. In one embodiment, methods of modulating the activity of mGluR1 are provided. In another embodiment, methods of modulating the activity of mGluR5 are provided. In still another embodiment, methods of simultaneously modulating the activities of both mGluR1 and mGluR5 are provided. The present invention also provides methods of treating diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of benzamide compounds. The present invention further provides methods of preventing diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of compounds.Type: ApplicationFiled: June 2, 2012Publication date: June 13, 2013Inventors: Richard D. Wood, William Welsh
-
Publication number: 20130142858Abstract: Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device.Type: ApplicationFiled: May 17, 2011Publication date: June 6, 2013Applicant: Aerie Pharmaceuticals, Inc.Inventors: Casey Kopczynski, Cheng-Wen Lin, Chris Sutay
-
Publication number: 20130137775Abstract: Bis- and tris-dihydroxyaryl compounds their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially AA amyloidosis, and the manufacture of medicaments for such treatment.Type: ApplicationFiled: January 23, 2013Publication date: May 30, 2013Inventors: Alan D. Snow, Thomas Lake, Luke Esposito, Kelsey Hanson, Marisa-Claire Yadon, Joel Cummings
-
Publication number: 20130131097Abstract: The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.Type: ApplicationFiled: January 10, 2013Publication date: May 23, 2013Applicant: ALLERGAN, INC.Inventor: Allergan, Inc.
-
Publication number: 20130123356Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof,Type: ApplicationFiled: October 18, 2012Publication date: May 16, 2013Applicant: UNIVERSITY COLLEGE LONDONInventors: Masahiro Okuyama, David Selwood, Cristina Visintin, David Baker, Gareth Pryce
-
Publication number: 20130121919Abstract: The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.Type: ApplicationFiled: June 11, 2012Publication date: May 16, 2013Applicant: The Trustees of Columbia University in the City of New YorkInventors: Yan FENG, Mauro Fa, Ottavio Arancio, Shi Xian Deng, Donald W. Landry, Yitshak Francis
-
Publication number: 20130109714Abstract: Provided is an unprecedented composition that is not a conventional symptomatic treatment, but makes possible the fundamental treatment of current neurodegenerative diseases by inhibiting oxidative-stress induced nerve-cell death. The disclosed neurodegenerative disease therapeutic agent includes a compound, or a salt of said compound, that inhibits oxidative-stress induced nerve-cell death to a high degree and is an agent used in the treatment of neurodegenerative diseases such as Parkinson's disease.Type: ApplicationFiled: March 25, 2011Publication date: May 2, 2013Applicant: National University Corporation Hokkaido UniversityInventor: Hiroyoshi Ariga
-
Publication number: 20130109750Abstract: The invention relates to novel arylamide derivatives having formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, where R1-R11, R?, R?, z and X are as defined in the claims. The arylamide derivatives of formula (I) have antiandrogenic properties. The invention also relates to compounds of formula (I) for use as a medicament and to pharmaceutical compositions comprising them and to their preparation.Type: ApplicationFiled: July 14, 2011Publication date: May 2, 2013Applicant: MEDEIA THERAPEUTICS LTDInventors: Jari Ratilainen, Milla Koistinaho, Anu Muona
-
Publication number: 20130101658Abstract: A drug insert is configured for use with an implant. The implant is configured for insertion into a lacrimal canaliculus. The drug insert includes a drug core comprising a therapeutic agent and a polymer; and a sheath body comprising material substantially impermeable to the therapeutic agent, wherein the drug core is positioned within the sheath body. The sheath body is configured to provide an exposed end of the drug core that releases therapeutic agent to an eye when the drug insert is disposed within the implant and the implant is positioned in the lacrimal canaliculus. A distal end of the drug core is sealed with a medical-grade adhesive.Type: ApplicationFiled: October 4, 2012Publication date: April 25, 2013Applicant: QLT INC.Inventor: QLT INC.
-
Publication number: 20130102678Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.Type: ApplicationFiled: December 14, 2012Publication date: April 25, 2013Applicant: ALLERGAN, INC.Inventor: Allergan, Inc.
-
Publication number: 20130090387Abstract: Citric acid and conjugate bases thereof are useful for stabilizing stabilized chlorine dioxide in the presence of therapeutically active agents and excipients in a composition. Ophthalmic compositions and methods related thereto are also disclosed herein.Type: ApplicationFiled: November 30, 2012Publication date: April 11, 2013Applicant: Allergan, Inc.Inventor: Allergan, Inc.
-
Publication number: 20130079414Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.Type: ApplicationFiled: March 4, 2010Publication date: March 28, 2013Applicant: ALLERGAN, INC.Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan
-
Publication number: 20130072520Abstract: Compounds of formula (I) have antibacterial activity: wherein R represents hydrogen or 1, 2 or 3 optional substituents; W is ?C(R1)— or ?N—; R1 is hydrogen or an optional substituent and R2 is hydrogen, methyl, or fluorine; or R1 and R2 taken together are —CH2—, —CH2CH2—, —O—, or, in either orientation, —O—CH2— or —OCH2CH2—; R3 is a radical of formula -(Alk1)m-(Z)p-(Alk2)n-Q wherein m, p and n are independently 0 or 1, provided that at least one of m, p and n is 1, Z is —O—, —S—, —S(O)—, —S(O2)—, —NH—, —N(CH3)—, —N(CH2CH3)—, —C(?O)—, —O—(C?O)—, —C(?O)—O—, or an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted divalent bicyclic heterocyclic radical having 5 to 10 ring atoms; Alk1 and Alk2 are optionally substituted C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene radicals, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —S(O2)—, —NH—, —N(CH3)—, or —N(CH2CH3)—; and Q is hydrogen, halogen, nitType: ApplicationFiled: November 28, 2011Publication date: March 21, 2013Applicant: Biota Scientific Management Pty LtdInventors: David BROWN, Ian COLLINS, Lloyd CZAPLEWSKI, David HAYDON
-
Publication number: 20130065934Abstract: The invention relates to fatty acid COX inhibitor derivatives; compositions comprising an effective amount of a fatty acid COX inhibitor derivative; and methods for treating or preventing a metabolic, autoimmune, inflammatory, or neurodegenerative disorder comprising the administration of an effective amount of a fatty acid COX inhibitor derivative.Type: ApplicationFiled: March 4, 2011Publication date: March 14, 2013Applicant: CATABASIS PHARMACEUTICALS, INC.Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu
-
Patent number: 8394799Abstract: Disclosed herein are an HIF-1 inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient. The HIF-1 inhibitor shows anticancer activity thanks to the inhibition activity against HIF-1, a transcription factor which plays an important role in the growth and metastasis of cancer, but not to general cytotoxicity. Thus, the HIF-inhibitor and a pharmaceutically acceptable salt thereof can be used as a therapeutic for various cancers such as liver cancer; stomach cancer and breast cancer. Also, the compound having inhibition activity against HIF-1 is useful in the treatment of diabetic retinopathy and arthritis, which are aggravated by HIF-1-mediated VEGF expression.Type: GrantFiled: July 3, 2007Date of Patent: March 12, 2013Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Jung Joon Lee, Jeong-Hyung Lee, Kyeong Lee, Young-Soo Hong, B. K. Shanthaveerappa, Yinlan Jin, Jin Hwan Kim, Xuejun Jin
-
Publication number: 20130053440Abstract: The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borate or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred.Type: ApplicationFiled: October 30, 2012Publication date: February 28, 2013Applicant: ALCON RESEARCH, LTD.Inventor: Alcon Research, Ltd.
-
Patent number: 8383683Abstract: The use of substituted amides for modulating the activity of 11?-hydroxysteroid dehydro-genase type 1 (11?HSD1) and the use of these compounds as pharmaceutical composi-tions, are described. Also a novel class of substituted amides, their use in therapy, phar-maceutical compositions comprising the compounds, as well as their use in the manufac-ture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11?HSD1 and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active gluco-corticoid is desirable.Type: GrantFiled: April 10, 2008Date of Patent: February 26, 2013Assignee: High Point Pharmaceuticals, LLCInventors: Soren Ebdrup, Henrik Sune Andersen
-
Publication number: 20130046024Abstract: Compositions for application and methods of application of a composition to modify hair. In one embodiment, a composition includes a compound (molecule) represented by: wherein A and B are individually selected from a hydrogen, a hydroxyl group and a halogen, with the proviso that when one of A and B is a hydroxyl group, the other of A and B is a hydrogen and when one of A and B is a halogen, the other of A and B is a halogen or a hydrogen; wherein Z is, for example, an aryl moiety; and wherein X1 and X2 are, for example, individually selected from a hydrogen and an alkyl moiety, wherein R1 and R2 are individually selected from an oxo, a hydroxyl or an ester group; wherein y is 0 or 1, x is 0 or 1 and x and y are not both 1, or a salt.Type: ApplicationFiled: September 28, 2012Publication date: February 21, 2013Applicant: PHARMA PATENT HOLDING INC.Inventor: Pharma Patent Holding Inc.
-
Publication number: 20130046023Abstract: A pharmaceutical composition, comprising a GluR2-lacking AMPAR antagonist as an active ingredient, is effective for preventing or treating mental diseases selected from the group consisting of posttraumatic stress disorder (PTSD), drug addiction, and phobia.Type: ApplicationFiled: October 24, 2012Publication date: February 21, 2013Applicant: SNU R&DB FOUNDATIONInventor: SNU R&DB Foundation
-
Publication number: 20130046014Abstract: The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.Type: ApplicationFiled: March 16, 2011Publication date: February 21, 2013Applicant: Novaliq GmbHInventor: Bastian Theisinger
-
Publication number: 20130045978Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.Type: ApplicationFiled: June 22, 2012Publication date: February 21, 2013Inventors: R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Steven Fung, Peer B. Jacobson, Lynne E. Rueter, Marina I. Strakhova, Jiahong Wang, Jyoti R. Patel, Qi Shuai, James T. Link, Jeffrey J. Rohde, Jurgen Dinges, Bryan K. Sorensen, Martin Winn, Hong Yong, Vince S. Yeh
-
Publication number: 20130041025Abstract: Described herein are compositions including prostaglandin analogs including prostamides and methods for using these compositions for increasing eyelash and eyebrow growth and hair growth on the scalp.Type: ApplicationFiled: March 23, 2011Publication date: February 14, 2013Applicant: ALLERGAN, INC.Inventors: John G. Walt, David F. Woodward, Amanda M. Vandenburgh
-
Publication number: 20130035284Abstract: The present invention concerns methods and compositions involving small molecule inhibitors for the treatment or prophylaxis of flavivirus infection, such as dengue virus and West Nile virus.Type: ApplicationFiled: March 5, 2012Publication date: February 7, 2013Applicant: The Board of Regents of the University of Texas SystemInventors: Stanley J. Watowich, Suzanne M. Tomlinson, Scott Gilbertson
-
Publication number: 20130035338Abstract: The current application is directed topical treatments that improve facial appearance by causing eyelids to naturally open more widely, or be more fully raised, as well as to treatment of ptosis and other eyelid-related conditions. These topical treatments include one or more of travoprost, dorzolamide hydrochloride, timolol maleate, unoprostone, latanoprost, bimatoprost, and related compounds currently used for treating glaucoma and ocular hypertension.Type: ApplicationFiled: August 6, 2012Publication date: February 7, 2013Inventor: Gordon Tang
-
Publication number: 20130035328Abstract: The invention relates to compounds having antiviral activity and methods utilizing the compounds to treat viral infections.Type: ApplicationFiled: July 19, 2012Publication date: February 7, 2013Inventors: Peter William Gage, Gary Dinneen Ewart, Lauren Elizabeth Wilson, Wayne Best, Anita Premkumar
-
Patent number: 8367733Abstract: The present invention is directed to methods for attenuating pain associated with a surgical site or an open wound by administration of single doses of a capsaicinoid formulation in proximity to a surgical site or wound opening.Type: GrantFiled: August 7, 2006Date of Patent: February 5, 2013Assignee: Vallinex, Inc.Inventors: Ronald Burch, Richard B. Carter, Jeff Lazar
-
Publication number: 20130030055Abstract: Described herein are compositions including at least one prostaglandin or prostamide and methods for using these compositions for increasing hair growth on the scalp eyebrow growth.Type: ApplicationFiled: March 23, 2011Publication date: January 31, 2013Applicant: ALLERGAN, INC.Inventors: John G. Walt, David F. Woodward, Amanda M. Vandenburgh
-
Patent number: 8362017Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Even more specifically, the invention provides compounds for modulating c-Kit kinase activity and methods of treating diseases mediated by c-Kit activity utilizing the compounds and pharmaceutical compositions thereof.Type: GrantFiled: August 27, 2004Date of Patent: January 29, 2013Assignee: Exelixis, Inc.Inventors: Wei Cheng, Erick Wang Co, Moon Hwan Kim, Rhett Ronald Klein, Donna T. Le, Amy Lew, John M. Nuss, Wei Xu, William Bajjalieh
-
Publication number: 20130011417Abstract: The present invention relates to colchicine derivatives expressed in chemical formula 1, or to pharmaceutically acceptable salts thereof, to a method for preparing said derivatives, and to a pharmaceutical composition comprising said derivatives. The colchicine derivatives according to the present invention exhibit superior immunomodulatory effects as compared with conventional immunomodulators or colchicines, and therefore can be valuably used as an immunomodulator for modulating an acute or chronic immune response in organ transplantation.Type: ApplicationFiled: February 18, 2011Publication date: January 10, 2013Inventors: Duck Jong Han, Sung-eun Yoo, Jeehee Suh
-
Publication number: 20130005665Abstract: Provided herein are compositions, which include an active pharmaceutical ingredient and macrogol 15 hydroxystearate, and methods for using the same for treating diseases or disorder.Type: ApplicationFiled: June 29, 2012Publication date: January 3, 2013Inventors: Anuradha V. Gore, Kevin S. Warner, Chetan P. Pujara, Richard S. Graham, Ajay Parashar, Mu-Lan Lee, Robert S. Jordan, Sukhon Likitlersuang
-
Publication number: 20130005802Abstract: Methods of treating Wnt/Frizzled-related diseases, comprising administering niclosamide compounds are provided. Methods of predicting whether a disease will respond to treatment with a niclosamide compound are also provided.Type: ApplicationFiled: September 21, 2010Publication date: January 3, 2013Inventors: Wei Chen, Minyong Chen, H. Kim Lyerly, Lawrence S. Barak, Robert Mook, Takuya Osada, Michael A. Morse
-
Publication number: 20130005718Abstract: Compositions and methods for managing or treating chronic pain are provided. More particularly, methods are provided for managing or treating chronic pain by administering to a patient in need thereof an effective amount of propofol or a propofol derivative having limited anesthetic properties. Methods of modulating HCN channel gating are also provided. Pharmaceutically acceptable compositions for, e.g., modulating HCN channel gating are further provided.Type: ApplicationFiled: August 10, 2010Publication date: January 3, 2013Inventors: Gareth R. Tibbs, Pamela Flood, Peter Goldstein
-
Publication number: 20130005759Abstract: MicroRNAs are a class of endogenous regulators of gene function. Aberrant regulation of microRNAs has been linked to various human diseases, most importantly cancer. Small molecule intervention of microRNA misregulation has the potential to provide new therapeutic approaches to such diseases. microRNA miR-122 is the most abundant microRNA in the liver and is involved in hepatocellular carcinoma development and hepatitis C virus (HCV) infection. Small molecule inhibitors and activators of the microRNA miR-122 are described, and methods for their identification are reported. These small molecule inhibitors reduce viral replication in liver cells and thus represent a new approach to the treatment of HCV infections. Moreover, small molecule activation of miR-122 in liver cancer cells selectively induced apoptosis through caspase activation, and thus has implications in cancer chemotherapy.Type: ApplicationFiled: January 21, 2011Publication date: January 3, 2013Inventors: Alexander Deiters, Douglas D. Young
-
Publication number: 20120329799Abstract: The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more carboxamide fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease. Group (A): a group consisting of thifluzamide, oxadixyl, pencycuron, benalaxyl-M, fenhexamid, furametpyr, isopyrazam, isotianil, mepronil, tecloftalam, boscalid, fluopyram, fluopicolide, carpropamid, diclocymet, mandipropamid, dimethomorph, flumorph, penthiopyrad, and bixafen.Type: ApplicationFiled: March 2, 2011Publication date: December 27, 2012Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: So Kiguchi, Soichi Tanaka, Mayuko Ozawa, Atsushi Iwata
-
Publication number: 20120322765Abstract: The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more inorganic fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease. group (A): a group consisting of fludioxonil, pencycuron, ametoctradin, chloroneb, chlorothalonil, oxine-copper, cyflufenamid, dichlofluanid, dicloran, diethofencarb, dinocap, dithianon, edifenphos, fenaminosulf, fentin, fluazinam, fluoroimide, flusulfamide, flutianil, fosetyl-Al, hydrargaphen, iprobenfos, metrafenon, milneb, penflufen, phosdiphen, phthalide, prothiocarb, pyrazophos, sedaxane, silthiofam, spiroxamine, tebufloquin, and tolyfluanid.Type: ApplicationFiled: March 2, 2011Publication date: December 20, 2012Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: So Kiguchi, Soichi Tanaka, Mayuko Ozawa, Atsushi Iwata
-
Publication number: 20120322882Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula (I) wherein the dashed bonds represent the presence or absence of a double bond which can be in the cis or trans configuration and A, B, Z, X, R1 and R2 are as defined in the specification and a penetration enhancer. Such compositions are used in stimulating hair growth of human or non-human animals.Type: ApplicationFiled: November 5, 2010Publication date: December 20, 2012Applicant: Allergan, Inc.Inventors: John T. Trogden, Adnan K. Salameh, Chetan P. Pujara
-
Publication number: 20120322883Abstract: The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more benzamide fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease.Type: ApplicationFiled: March 2, 2011Publication date: December 20, 2012Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: So Kiguchi, Soichi Tanaka, Mayuko Ozawa, Atsushi Iwata
-
Publication number: 20120322769Abstract: A method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound described herein.Type: ApplicationFiled: February 16, 2011Publication date: December 20, 2012Applicants: DUKE UNIVERSITY, UWM RESEARCH FOUNDATIONInventors: Ching-Hong Yang, Xin Chen, Eric J. Toone
-
Patent number: 8334281Abstract: Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.Type: GrantFiled: December 22, 2009Date of Patent: December 18, 2012Assignee: Evoke Pharma, Inc.Inventors: Matthew J. D'Onofrio, David A. Gonyer, Shirish A. Shah, Stuart J. Madden
-
Publication number: 20120301423Abstract: The present invention relates to derivatives of ?,?-disubstituted amide compounds which comprise a substituted aryl at the ? carbon such that the substituent provides a means for attachment or incorporation of the compound to or in a polymer. The provision of such a substituent on the aryl has surprisingly been found not only to permit attachment to or incorporation in a polymer but also retention of useful antifouling activity. In embodiments, the substituent is selected from hydroxyl, ethers, es ters, carboxyls, alkylsilyls and alkenyls. Experiments demonstrate that antifouling activity can be as good or better as the corresponding unsubstituted compound and that polymers functionalised so as to include or be formed from the substituted compound can be used to reduce settlement.Type: ApplicationFiled: February 2, 2011Publication date: November 29, 2012Applicants: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, MARITIME AND PORT AUTHORITY OF SINGAPORE, NATIONAL UNIVERSITY OF SINGAPOREInventors: Christina Li Lin Chai, Brendan Adrian Burkett, Serena Lay Ming Teo, Daniel Rittschof, Serina Siew Chen Lee, Gary Howard Dickinson, Han Hong
-
Patent number: 8318801Abstract: The invention relates to a compound represented by the following formula (I): and pharmaceutically acceptable salts, stereoisomers, enantiomers, prodrugs and solvates thereof. The compounds are useful as an agent for enhancing the neurite outgrowth and preventing or treating of diseases associated with HDAC in particular, tumor or cell proliferative diseases. In particular, the compounds of the invention can be used as an agent for anti-cancer, anti-diabetic, and anti-neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Spinocerebellar Ataxias (SCA), and human spinal muscular atrophy (SMA).Type: GrantFiled: May 24, 2011Date of Patent: November 27, 2012Assignee: Naturewise Biotech & Medicals CorporationInventors: Chung-Yang Huang, Chia-Nan Chen, Wei-Jan Huang, Chia-Wei Lin, Jing-Shi Huang, Li-Ling Chi, Ai-Ling Chen, Chi-Yun Lee, Yu-Chen Huang
-
Publication number: 20120289512Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.Type: ApplicationFiled: May 10, 2012Publication date: November 15, 2012Applicant: ABBOTT LABORATORIESInventors: R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Steven Fung, Peer B. Jacobson, Lynne E. Rueter, Marina I. Strakhova, Jiahong Wang, Jeffrey J. Rohde, Qi Shuai, James T. Link, Jyoti R. Patel, Jurgen Dinges, Bryan K. Sorensen, Hong Yong, Vince S. Yeh, Ravi Kurukulasuriya
-
Publication number: 20120289603Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.Type: ApplicationFiled: July 17, 2012Publication date: November 15, 2012Applicant: ALLERGAN, INC.Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin